Novartis Pharma B.V.

Location

Noord-Holland

Founded

1948-02-10

Risk Signals

21159 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Recent Articles about Novartis Pharma B.V.

Live alerts from global media, monitored by Business Radar

Require Medical Safety Lead at Novartis

2024-10-05 (pharmatutor.org)

Require Medical Safety Lead at Novartis

Bachelor of Science in Pharmacy, Bachelor of Science in Nursing, PharmD, PhD in relevant field or Medical Degree MBBS or MD required.

Read more
CDSCO Approves safety, efficacy data with DMC report for Novartis' antimalarial drug Cipargamin

2024-09-14 (medicaldialogues.in)

CDSCO Approves safety, efficacy data with DMC report for Novartis' antimalarial drug Cipargamin

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the safety and efficacy data with the DMC (Data Monitoring...

Read more
CDSCO Approves safety, efficacy data with DMC report for Novartis' antimalarial drug Cipargamin

2024-09-14 (medicaldialogues.in)

CDSCO Approves safety, efficacy data with DMC report for Novartis' antimalarial drug Cipargamin

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the safety and efficacy data with the DMC (Data Monitoring...

Read more
Availability of medicines in town and in hospital

2024-02-01 (vidal.fr)

Availability of medicines in town and in hospital

Between January 26 and February 1, 2024, the National Medicines and Drug Safety Agency

Read more
Pharmalittle: We're reading about GLP-1 drugs' safety, Novartis nixing a deal, and more

2024-01-12 (statnews.com)

Pharmalittle: We're reading about GLP-1 drugs' safety, Novartis nixing a deal, and more

A preliminary FDA evaluation did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions.

Read more
Pharmalittle: We're reading about GLP-1 drugs' safety, Novartis nixing a deal, and more

2024-01-12 (statnews.com)

Pharmalittle: We're reading about GLP-1 drugs' safety, Novartis nixing a deal, and more

A preliminary FDA evaluation did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions.

Read more
Zolgensma may safely benefit older, heavier SMA children: Study

2023-12-15 (smanewstoday.com)

Zolgensma may safely benefit older, heavier SMA children: Study

In a real-world study, Zolgensma treatment did not cause any serious long-term safety problems for a handful of heavier children with SMA.

Read more
Zolgensma may safely benefit older, heavier SMA children: Study

2023-12-15 (smanewstoday.com)

Zolgensma may safely benefit older, heavier SMA children: Study

In a real-world study, Zolgensma treatment did not cause any serious long-term safety problems for a handful of heavier children with SMA.

Read more
BLOG: GA patients deserve better drug adoption

2023-11-08 (healio.com)

BLOG: GA patients deserve better drug adoption

More than a decade ago, I told my wife’s grandfather that, despite all our advances in medicine, we didn’t have a treatment for his geographic atrophy.

Read more
Weir: This is how the fire brigade rehearses dangerous operations under realistic conditions

2023-10-09 (suedkurier.de)

Weir: This is how the fire brigade rehearses dangerous operations under realistic conditions

Fire departments can also simulate difficult situations with a special fire container. Take a look behind the scenes of an exercise here.

Read more
Don't Miss a Beat: ESC Heart Failure Association Preview

2023-05-19 (hcplive.com)

Don't Miss a Beat: ESC Heart Failure Association Preview

In this episode of Don’t Miss a Beat, hosts sit down at ESC HFA to discuss key takeaways from the ACC's expert clinical decision pathway and preview HFpEF data scheduled to be presented during the meeting.

Read more
Novartis cans branaplam after seeing Huntington's safety signal, delays orphan drug over slow enrollment

2023-02-01 (fiercebiotech.com)

Novartis cans branaplam after seeing Huntington's safety signal, delays orphan drug over slow enrollment

Novartis has delivered the coup de grâce to its ailing branaplam program, stoppin | Novartis has delivered the coup de grâce to its ailing branaplam program, stopping development of the splicing modulator in Huntington’s disease in the wake of a safety signal.

Read more

Never miss a headline about Novartis Pharma B.V.

Set up smart alerts with Business Radar and receive real-time updates on any new risk signal or major news story.

  • ✔️ Used by 100+ compliance teams and analysts
  • ✔️ Covers 154M+ sources in 40+ languages